Plan Exportador de Algas Marinas a Japón

Generar un plan exportador que permita incursionar algas marinas colombianas al mercado japonés.En un mundo globalizado donde el éxito de las empresas es cada vez más difícil por la competencia se deben buscar nuevas alternativas que signifiquen una ventaja absoluta logrando auto sostenimiento y crecimiento económico, por esta razón las compañías todos los días buscan abrir nuevos mercados, en este caso el objetivo principal es realizar un plan exportador de algas marinas a Japón, se escogió este producto por el potencial de producción del país exportador, por la demanda del producto en el país asiático, y por la baja producción interna. El plan exportador es dirigido a la región de Tohoku allí más del 40 % del producto lo comercializa la prefectura de Iwate y se vende en supermercados, grandes superficies y principalmente en mercados locales, el objetivo principal del plan es incursionar todos estos canales distribuyéndolo directamente con la prefectura, se estima que cada nipón consume entre 2.5 kg y 3 kg de algas mensualmente y las producidas en Colombia serian apetecidas por su buena calidad. Realizar este plan fue todo un reto porque la cultura japonesa es totalmente diferente a la colombiana, la información que se recolectó fue a través de una investigación ardua y al final se llega a la conclusión de que el proyecto es viable, se elaboran estrategias, recomendaciones para que el plan sea lo más efectivo posible, todo esto gracias a la aplicación de matrices de diagnóstico y el esfuerzo en la investigación

Case-Serie of 4 COVID-19 patients hospitalized in an intensive care unit in a hospital institution in Barranquilla, Colombia

Objetivo: Presentar una serie de casos de COVID-19 con requerimiento de ingreso a Unidad de Cuidados Intensivos. Métodos: La información fue tomada de las historias clínicas, y su evaluación y diagnóstico fue realizado mediante estudios paraclínicos en sangre, orina, PCR e imágenes diagnósticas en 4 pacientes con diferentes comorbilidades y nexo epidemiológico presente para desarrollo de la enfermedad. El caso 1 desarrolló falla orgánica múltiple, incluyendo injuria renal aguda con una estancia en UCI de 4 dias antes de su fallecimiento, mientras los casos 2, 3 y 4 tuvieron una evolución favorable y fueron dados de alta de UCI. Los cuatro casos fueron manejados con cloroquina 300 mg via oral cada 12 horas y azitromicina 1 gr via oral cada 24 horas durante 5 dias sin complicaciones ni toxicidad asociada. Conclusiones: Se requieren estudios multicéntricos rápidos que orienten científicamente hacia un mejor abordaje diagnóstico y manejo, en el contexto de una enfermedad con un comportamiento clínico-epidemiologico que debe estudiarse en profundidad y que probablemente cobrará muchas vidas, ademas, debido a la ausencia de pruebas diagnósticas rápidas, la utilización de una clasificación basada en la severidad de lesiones radiológicas llamada CO-RADS (Covid-19 Imaging Reporting and Data System), podría ser de gran importancia para instalar de manera temprana los tratamientos farmacológicos disponibles y la asistencia respiratoria mecánica precoz.Objective: To present a COVID-19 case series with clinical admission criteria to Intensive Care Unit. Methods: Patients information was obtained from medical records, and daily clinical evaluation whereas diagnosis was carried out through paraclinical studies in blood, urine, PCR and diagnostic images in 4 patients with different comorbidities and epidemiological link for the development of COVID19. The case 1 developed multiple organ failure, including acute kidney injury with an ICU stay of 4 days before his death, while cases 2, 3 and 4 had a favorable evolution and were discharged from the ICU. All four cases were managed with chloroquine 300 mg orally every 12 hours and azithromycin orally every 24 hours for 5 days without complications or associated toxicity. Conclusions: rapid multicenter studies are required to scientifically guide a better diagnostic and management approach, in the context of a disease with a clinical-epidemiological behavior that must be studied in depth and will probably take many lives. In addition, due to the absence of sufficiently rapid tests, the use of a classification based on the severity of radiological lesions called CO-RADS (Covid-19 Imaging Reporting and Data System), could be of great importance to install av

Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. Methods: A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Findings: Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Interpretation: Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. Funding: National Institute for Health and Care Research